Supernus Pharmaceuticals
SUPN
312 hedge funds and large institutions have $2.34B invested in Supernus Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 106 increasing their positions, 115 reducing their positions, and 36 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
56% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 36
18% more capital invested
Capital invested by funds: $1.98B → $2.34B (+$361M)
5% more funds holding
Funds holding: 297 → 312 (+15)
2.45% more ownership
Funds ownership: 96.94% → 99.38% (+2.4%)
8% less repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 115
32% less call options, than puts
Call options by funds: $5.1M | Put options by funds: $7.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Provident Investment Management
Novi,
Michigan
|
+$22.5M |
| 2 |
CRCP
Copper Rock Capital Partners
Boston,
Massachusetts
|
+$22.3M |
| 3 |
JP Morgan Chase
New York
|
+$12M |
| 4 |
Renaissance Technologies
New York
|
+$11.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$22M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$18.2M |
| 3 |
SI
Scout Investments
Kansas City,
Missouri
|
-$17.4M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$13.5M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.83M |
SUPN Hedge Fund Activity: Q1 2018 in Review
312 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2018, worth a combined $2.34B — up 18% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new SUPN positions and 36 closed out — a net gain of 20 holders — while 106 added to existing stakes and 115 trimmed.
The largest buyer was Provident Investment Management, opening a new position worth an estimated $22.5M. The largest seller was Emerald Advisers, exiting entirely with an estimated $22M sold.
- 312 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2018, up from 297 in Q4 2017.
- Funds reported $2.34B of Supernus Pharmaceuticals stock for Q1 2018, up 18% quarter-over-quarter.
- 56 funds opened new Supernus Pharmaceuticals positions in Q1 2018 and 36 closed out, a net change of +20 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2018 was Provident Investment Management, an estimated $22.5M added.
- The largest Supernus Pharmaceuticals seller in Q1 2018 was Emerald Advisers, an estimated $22M sold.
Based on aggregated 13F filings for Q1 2018.